Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 déc. 2025 08h00 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter...
05 nov. 2025 08h30 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...
27 oct. 2025 08h30 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS” or the...
15 sept. 2025 08h00 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...
26 août 2025 08h00 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage...
19 août 2025 08h12 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter...
11 août 2025 08h00 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) --...
23 juil. 2025 08h00 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the...
10 juil. 2025 16h05 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the...
30 juin 2025 15h15 HE | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter...

Page suivante